People might attribute midnight bouts of chest pain or waves of nausea to food poisoning, stress or a stubborn case of indigestion, but Rutgers Health researchers suggest that knowing your family's ...

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...

Combination Therapy Improves Survival in Biliary Tract Cancer A randomized phase 3 trial confirms cisplatin plus gemcitabine improves survival in biliary tract cancer and gets high marks from Dr.

Nagoya University researchers and their collaborators have found that minimally invasive laparoscopic surgery significantly reduces blood loss and improves jaundice recovery compared to traditional ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Wednesday granted accelerated approval to zanidatamab ...

ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...

Biliary atresia (BA) is a rare, progressive inflammatory disease of the biliary system that is the leading cause of neonatal cholestasis, characterised by fibrosis and obliteration of the bile ducts.

Midtown Gastroenterology and Liver Disease in Des Plaine, Ill., has added Faris Murad, MD.  Dr. Murad is a gastroenterologist with more than two decades of experience in the diagnosis and treatment of ...

Keytruda, combined with gemcitabine and cisplatin, is approved for advanced biliary tract cancer, showing a 17% reduction in death risk compared to chemotherapy alone. The KEYNOTE-966 trial indicated ...

The liver produces bile, which the intestine uses for digestion. For the transport of bile, the liver relies on a network of microscopic tubings, known as bile canaliculi, formed by liver cells called ...

Genfit Plans to Test Its Drug in Second Liver Disease French drugmaker Genfit SA on Thursday said it would begin a midstage trial this year of its experimental drug elafibranor to treat primary ...